Epilepsy is one of the most common neurological conditions, with more than 2% of the population worldwide affected according to the latest study [1]. As a chronic disease, epilepsy requires long-term treatment with anti-epileptic drugs (AEDs) [2]. Moreover, up to 30% of patients with epilepsy remain resistant to the standard therapy despite the multitude of available AEDs such as carbamazepine (CBZ), sodium valproate, and phenytoin (PHT) [3,4]. Oxcarbazepine (OXC), a 10-keto derivative of CBZ, has emerged as a relatively new AED.

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...